Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome
Clinical trial NCT01325220 · COMPLETED
Trial details
- NCT number
- NCT01325220
- Sponsor
- Seaside Therapeutics, Inc.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2011-06-01
- Primary completion
- 2013-06-01
- Enrollment
- 172
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.